KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Accumulated Expenses: 2018-2025

Historic Other Accumulated Expenses for Amneal Pharmaceuticals (AMRX) over the last 4 years, with Sep 2025 value amounting to $40.6 million.

  • Amneal Pharmaceuticals' Other Accumulated Expenses rose 34.52% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 34.52%. This contributed to the annual value of $31.8 million for FY2024, which is 58.75% down from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Other Accumulated Expenses stood at $40.6 million, which was down 2.21% from $41.5 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Other Accumulated Expenses registered a high of $275.3 million during Q2 2022, and its lowest value of $30.1 million during Q1 2024.
  • For the 3-year period, Amneal Pharmaceuticals' Other Accumulated Expenses averaged around $50.5 million, with its median value being $41.5 million (2025).
  • In the last 5 years, Amneal Pharmaceuticals' Other Accumulated Expenses soared by 85.32% in 2022 and then crashed by 72.03% in 2023.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Other Accumulated Expenses stood at $58.0 million in 2021, then skyrocketed by 85.32% to $107.5 million in 2022, then declined by 28.37% to $77.0 million in 2023, then crashed by 58.75% to $31.8 million in 2024, then spiked by 34.52% to $40.6 million in 2025.
  • Its last three reported values are $40.6 million in Q3 2025, $41.5 million for Q2 2025, and $43.5 million during Q1 2025.